Hos psoriasis patienter behandlet med infliximab som vedligeholdelsesbehandling uden samtidige immunmodulerende midler udviklede 28% antistoffer mod infliximab.
In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab.